India Glass Pharmaceutical Packaging Materials Market: 8.11% Growth Forecast – Key Trends & Players - Market Research

Market Outlook

In 2024, the India Glass Pharmaceutical Packaging Materials Market was valued USD 983.00 Million and is projected to expand at a CAGR of 8.11% through 2030 propelled by growth of the pharmaceutical industry, tighter regulations, and the growing need for safe and ecofriendly packaging. The Indian pharmaceutical industry is one of the fastest growing industries and is expected to capture 3.5% share in global exports. This growth calls for high-quality glass packaging for drugs, vaccines, and biologics. In addition, the type I borosilicate glass enhanced chemical resistance and the government initiative of “Make in India” are further opening up the market.

In 2024, the increase in chronic diseases and the growth of biopharmaceuticals drove the demand for injectables, which made up over 40% of the market share. The rise in the adoption of prefilled syringes and vials for vaccines and biologics are further driving growth of the market. On the other hand, high competition from low-cost plastic alternatives and high production costs remain as barriers to growth. There is however, great promise in lightweight and eco-friendly innovations offering glass packaging in the years to come.

Browse market data Figures spread through 85 Pages and an in-depth TOC on "India Glass Pharmaceutical Packaging Materials Market” - https://www.techsciresearch.com/report/india-glass-pharmaceutical-packaging-materials-market/26871.html

Market Driver Analysis

The boom in the pharmaceutical domain, which is currently the third-largest in the world by volume, is benefiting the India Glass Pharmaceutical Packaging Materials Market. The country produces over 60,000 generic drugs belonging to over 60 therapeutic categories. In addition, the rising production of generic medicines and vaccines, as well as biologics, calls for superior quality glass packaging to guarantee stability and compliance to USP, EP, and IP standards.

Demand for injectable medicines is rapidly increasing, especially from diabetes, cancer, and cardiovascular disease patients, which is also a major driver. Injectable medicines need sterile and chemically inactive packages, thus the preferred option is borosilicate glass vials and ampoules. There was a huge spike in demand during the COVID-19 pandemic when India alone supplied over 2 billion doses of vaccines, the majority of which were packaged in glass vials.

Regulatory mandates also play an important role as the Indian Pharmacopoeia Commission (IPC) and CDSCO have strict regulations for pharmaceutical packaging that encourage Type I and Type II glass use for sensitive formulations. In addition, these policies tend to drive packaging sustainability which leads to less stress on the environment compared to plastic.

An increase in Foreign Direct Investment (FDI) to Pharma ($20.3 billion in 2023) along with the growth of contract manufacturing further increases need. In order to satisfy the growing demand for high-quality packaging, companies are investing in advanced technologies for glass manufacturing such as tubing and molded glass.

Market Trends Analysis

Increased Demand For Prefilled Syringes And Cartridges – With the rise of biologics and biosimilars, the demand for prefilled syringes is on the rise due to accurate dosing and lower contamination chances. Gerresheimer and Schott AG are boosting their capacity of prefilled glass syringe production in India.
Dominance of Type I Borosilicate Glass In The Market – Type I glass leads the market for container types meter due to its exceptional chemical and thermal properties for parenteral drugs. Over 65% of injectable medicines sold in India are contained in borosilicate glass vials.
Green and Light Container – Producers want to lower the material costs and carbon footprint by lightweight thin-walled glass. Piramal Glass has produced vials that weight less and therefore have decreased the cost of shipping by 15%-20%.
Automated Glass Production – Defect reduction and efficiency improvements are being accomplished using Industry 4.0 technologies such as AI powered inspection systems.
Increase in Sales of Mistake-Prone Glass – Light-sensitive drugs are best suited for amber glass bottles in contrast to pH-sensitive formulations which are best suited for neutral glass.

Download Free Sample Report - https://www.techsciresearch.com/sample-report.aspx?cid=26871

Market Challenges Analysis

Severe Expenses on Manufacturing – Glass production is energy intensive raising the operational cost. Unlimited detrimental competition exists with polymer and plastic substitutes.
High Cost of Logistics Due to Breakage – Appliance for transportation with glass containers is liable to physical injury. This results in high logistics expenditure and ineffective supply chains.
Competition from Substitute Materials – Plastics and polymer materials are gaining more preference due to the light weight and break resistance of Cyclic Olefin Copolymers (COC) and PET.
Geopolitical Supply Issues – The market volatility in the price of raw materials like silica sand and soda ash loses the guarantee of uniform production.
ISO Compliance Limitations – Grantee of Good Manufacturing Practice (GMP) and ISO computation signifying promise embodies vast expense on primary quality control procedures and laboratory tests.

Segmentations

By Product:

Ampoules
Bottles
Vials
Syringes
Cartridges

By Material:

Type I Glass
Type II Glass
Type III Glass

By Application:

Oral Medications
Injectable Medications
Nasal Medications

Regional Analysis

Western India (Maharashtra, Gujarat) – This region leads by holding 40% of the market share because it’s the location of pharma hubs in Mumbai, Pune and Ahmedabad. Not only that, Gujarat accounts for 28% of India's pharma exports which is huge.
Southern India (Karnataka, Tamil Nadu, Telangana) – 25% market share which is attributed to the biotech industry in Bengaluru and bulk drug manufacturing in Hyderabad.
Northern India (Delhi NCR, Himachal Pradesh) – 20% share, especially with Baddi (HP) emerging as a generic drugs production cluster.
Eastern India (West Bengal, Odisha) – Having growth due to cheap manufacturing facilities available.

Primary Catalysts and Hindrances

Catalysts: